Clene Inc. Form 8-K Summary
Business Context and Reporting Period
Clene Inc. (CLNN), a biotechnology company focused on nanomedicine, filed this Current Report on Form 8-K on January 28, 2025. The filing details a material definitive agreement regarding a grant subaward amendment with Columbia University, the prime awardee of a National Institutes of Health (NIH) grant.
Key Financial Metrics
This filing does not contain comprehensive financial statements, revenue, profit, cash flow, or debt metrics. The only specific financial figure disclosed is the funding amount associated with the grant amendment:
- Grant Funding: Up to $8.0 million in reimbursement for expenses.
- Grant Period: September 1, 2024, to August 31, 2025 (Second year of the program).
- Total Grant Context: Part of a four-year, $45.1 million NIH Grant awarded in October 2023.
Material Changes
The primary material change is the execution of "Subaward Amendment 1" on January 28, 2025. This amendment formalizes the funding for the second year of the Expanded Access Program (ACT-EAP) for the treatment of amyotrophic lateral sclerosis (ALS) using the Company's CNM-Au8 therapy. The amendment maintains the terms of the original subaward agreement entered into on April 3, 2024.
Outlook, Risks, and Management Commentary
The filing confirms the continuation of the ACT-EAP, which operates under the Accelerating Access to Critical Therapies for ALS Act. The program is a collaboration between Clene Inc., Columbia University, and Synapticure. No specific forward-looking guidance, risk factors, or unusual items were disclosed in this specific report beyond the standard incorporation of the amendment text.
Investor Verification Checklist
- Verify the specific terms and conditions of the Subaward Amendment 1 filed as Exhibit 10.1.
- Confirm the status of the first-year subaward and any unspent funds from the initial period.
- Review the total remaining balance of the $45.1 million NIH Grant for years three and four.
- Assess the progress of the ACT-EAP patient enrollment and clinical data generation for CNM-Au8.